Abstract: A method for setting dynamic triggers for event recordings for a vehicle and related aspects are disclosed. The method includes obtaining sensor data samples captured by one or more sensors of the vehicle, generating sensor data embeddings from the sensor data samples, receiving a query embedding, identifying one or more sensor data embeddings within the multi-dimensional vector space based on a proximity to the received query embedding within the multi-dimensional vector space, and storing sensor data samples represented by the identified one or more sensor data embeddings.

Abstract: The present disclosure relates to the field of laboratory diagnostics. Specifically, means and methods are disclosed for determining a patient's risk of suffering from acute kidney injury after a surgical procedure based on the detection of GDF-15, troponin T and/or a natriuretic peptide.

Abstract: Method for determination of whether a subject suffers from intermittent atrial fibrillation based on the determination of the amount of a Troponin T in a sample in a patient suffering from atrial fibrillation using a binding assay. Kits and devices adapted to carry out the methods are also provided.

Abstract: Methods and systems for diagnosing functional and/or structural abnormalities of the heart preceding heart failure, and for predicting the risk of developing heart failure, in a subject comprising measuring a cardiac troponin in a sample and comparing the measurement to a reference value. Other markers, including GDF15 and IGFBP7 are also measured in some embodiments.

Abstract: Method for determination of whether a subject suffers from intermittent atrial fibrillation based on the determination of the amount of a Troponin T in a sample in a patient suffering from atrial fibrillation using a binding assay. Kits and devices adapted to carry out the methods are also provided.

Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.

Abstract: Methods and systems for diagnosing functional and/or structural abnormalities of the heart preceding heart failure, and for predicting the risk of developing heart failure, in a subject comprising measuring a cardiac troponin in a sample and comparing the measurement to a reference value. Other markers, including GDF15 and IGFBP7 are also measured in some embodiments.

Abstract: The present invention relates to a bucket wheel excavator whose bucket wheel is rotationally drivable and is supported at a pivotable bucket wheel boom and to a method of controlling such a bucket wheel excavator. In accordance with the invention, a mass flow and/or material flow adopted on the removal conveyor after a specific advance on the pivoting of the bucket wheel at the predetermined pivot angle speed is/are determined over the pivot angle, a desired mass flow and/or volume flow is/are specified on the removal conveyor, and then the previously specified pivot angle speed is automatically corrected using the determined mass flow and/or volume flow and the specified desired mass flow and/or volume flow to then perform the pivot cycle at the corrected pivot angle speed of the bucket wheel.

Abstract: The present invention relates to a method for diagnosing a transitory ischemic attack (TIA) in a subject who is suspected to have exhibited a transitory ischemic attack, but who did not exhibit a stroke. The method is based on the determination of the amount of NT-proANP in a sample from said subject. Moreover, the present invention is directed to a method for diagnosing an acute cerebral ischemic event in a subject based on the determination of the amounts of NT-proBNP and NT-proANP in a sample from a subject. The method further comprises the step of calculating a ratio of the amounts of NT-proBNP and NT-proANP. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention.

Abstract: The present invention relates to a method for diagnosing a transitory ischemic attack (TIA) in a subject who is suspected to have exhibited a transitory ischemic attack, but who did not exhibit a stroke. The method is based on the determination of the amount of NT-proANP in a sample from said subject. Moreover, the present invention is directed to a method for diagnosing an acute cerebral ischemic event in a subject based on the determination of the amounts of NT-proBNP and NT-proANP in a sample from a subject. The method further comprises the step of calculating a ratio of the amounts of NT-proBNP and NT-proANP. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention.

Abstract: The present disclosure relates to the field of laboratory diagnostics. Specifically, means and methods are disclosed for determining a patient's risk of suffering from acute kidney injury after a surgical procedure based on the detection of GDF-15, troponin T and/or a natriuretic peptide.

Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.

Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.

Abstract: The disclosure relates to assessing heart failure in vitro by measuring the concentration of the marker mimecan in a sample, and optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration of mimecan and the one or more other marker(s) to reference concentrations of this (or these) marker(s) as established in a reference population. The one or more markers may be selected from the group comprising a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation. Also disclosed are the use of mimecan as a marker protein in the assessment of heart failure, a marker combination comprising mimecan, and a kit for measuring mimecan.

Abstract: Method for determination of whether a subject suffers from intermittent atrial fibrillation based on the determination of the amount of a Troponin T in a sample in a patient suffering from atrial fibrillation using a binding assay. Kits and devices adapted to carry out the methods are also provided.

Abstract: The present invention relates to a method for identifying a subject being susceptible to anti-angiogenesis therapy based in determining the amount of a cardiac troponin in a sample of the subject and comparing the amount to a suitable reference amount. Also encompassed by the present invention are kits and devices adapted to carry out the method of the present invention.

Abstract: The present disclosure relates to the field of laboratory diagnostics. The present disclosure provides means and methods for differentiating between an acute circulatory event and an ischemic event, as the cause underlying an acute medical event of a patient.

Abstract: The present disclosure relates to the field of laboratory diagnostics. The present disclosure provides means and methods for differentiating between an acute circulatory event and an ischemic event, as the cause underlying an acute medical event of a patient.

Abstract: Systems, kits, and methods for predicting the risk of an adverse event related to acute kidney injury AKI as a consequence of a surgical intervention in a subject. Embodiments of the system and methods include means and steps for determining an amount of liver-type fatty acid binding protein (L-FABP) in a sample, such as a urine-sample of a subject; comparing the amounts of the L-FABP with a reference amount, and predicting the risk of an adverse event related to acute kidney injury as a consequence of surgical intervention in the subject.

Abstract: Method for determination of whether a subject suffers from intermittent atrial fibrillation based on the determination of the amount of a Troponin T in a sample in a patient suffering from atrial fibrillation using a binding assay. Kits and devices adapted to carry out the methods are also provided.